Key result
Kcne3 is a VEGFA-inducible gene selectively expressed by vascular endothelial tip cells, exhibiting a ~30-fold increase in expression following VEGFA treatment.
Why the study?
Despite endothelial tip-cells being a primary therapeutic focus in neovascular pathologies, there remains a paucity of specific endothelial tip-cell markers.
Answers are grounded in this paper and cite their sources.
Kcne3 is identified as a highly specific, VEGFA-inducible marker for vascular endothelial tip cells, providing a novel tool for studying and targeting angiogenesis.
Angiogenesis is largely driven by motile endothelial tip-cells capable of invading avascular tissue domains and enabling new vessel formation. Highly responsive to Vascular Endothelial Growth-Factor-A (VEGFA), endothelial tip-cells also suppress angiogenic sprouting in adjacent stalk cells, and thus have been a primary therapeutic focus in addressing neovascular pathologies. Surprisingly, however, there remains a paucity of specific endothelial tip-cell markers. Here, we employ transcriptional profiling and a lacZ reporter allele to identify Kcne3 as an early and selective endothelial tip-cell marker in multiple angiogenic contexts. In development, Kcne3 expression initiates during early phases of angiogenesis (E9) and remains specific to endothelial tip-cells, often adjacent to regions expressing VEGFA. Consistently, Kcne3 activation is highly responsive to exogenous VEGFA but maintains tip-cell specificity throughout normal retinal angiogenesis. We also demonstrate endothelial tip-cell selectivity of Kcne3 in several injury and tumor models. Together, our data show that Kcne3 is a unique marker of sprouting angiogenic tip-cells and offers new opportunities for investigating and targeting this cell type.
No takes yet. Share an insight, caveat, or question.
Deckelbaum et al. (2019) studied Angiogenesis. VEGFA vs. hFc (human IgG1) was evaluated on Kcne3 gene expression in retinal endothelial cells (~30-fold increase). Kcne3 is a VEGFA-inducible gene selectively expressed by vascular endothelial tip cells, exhibiting a ~30-fold increase in expression following VEGFA treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: